How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,010 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Benign prostatic hyperplasia

Benign prostatic hyperplasia Benign prostatic hyperplasia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Benign prostatic hyperplasia Last reviewed: February 2019 Last updated: September 2018 Summary Multi-factorial involving smooth muscle hyperplasia, prostatic enlargement, and bladder dysfunction, as well as input from the central nervous system. Presents with both storage symptoms (frequency, urgency, nocturia (...) invasive therapy. Failure of medical management or renal complications are indications for surgical intervention. There are a host of procedural treatments, which have unique risk/benefit profiles for consideration. Definition Lower urinary tract symptoms (LUTS) caused by bladder outlet obstruction due to benign prostatic hyperplasia (BPH), also known as benign prostatic enlargement (BPE), are predominantly due to 2 components: a static component related to an increase in benign prostatic tissue

2018 BMJ Best Practice

22. Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia

Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia Date of origin: 1995 Last review date: 2014 ACR Appropriateness Criteria ® 1 Lower Urinary Tract Symptoms: Suspicion of BPH American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Lower Urinary Tract Symptoms: Suspicion of Benign Prostatic Hyperplasia Radiologic Procedure Rating Comments RRL* US pelvis (bladder and prostate) transabdominal 6 Consider this procedure after patient voids to measure (...) without IV contrast 1 ???? CT abdomen and pelvis with IV contrast 1 ???? Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate *Relative Radiation Level ACR Appropriateness Criteria ® 2 Lower Urinary Tract Symptoms: Suspicion of BPH LOWER URINARY TRACT SYMPTOMS: SUSPICION OF BENIGN PROSTATIC HYPERPLASIA Expert Panel on Urologic Imaging: Barak Friedman, MD 1 ; John R. Leyendecker, MD 2 ; M. Donald Blaufox, MD, PhD 3 ; Steven C. Eberhardt, MD 4 ; Pat F. Fulgham

2019 American College of Radiology

23. Male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH)

Male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH) Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed. Besides, it's possible to , or you can view flippdf Either scripts and active content are not permitted to run or Adobe Flash Player version 10.0.0 or greater is not installed. Besides, it's possible

2018 Canadian Urological Association

24. Prostate artery embolisation for benign prostatic hyperplasia. Decision Support Document 105.

Prostate artery embolisation for benign prostatic hyperplasia. Decision Support Document 105. Prostate artery embolisation for benign prostatic hyperplasia - Repository of AIHTA GmbH English | Browse - - - Prostate artery embolisation for benign prostatic hyperplasia Vreugdenburg, Thomas and Wild, C. (2017): Prostate artery embolisation for benign prostatic hyperplasia. Decision Support Document 105. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 933kB (...) . A new evaluation is proposed in the year 2021, if results from RCTs are available. Item Type: Decision Support Document Keywords: Benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS), prostate artery embolisation (PAE) Subjects: > > > > > Language: English Series Name: Decision Support Document 105 Deposited on: 17 Jul 2017 10:05 Last Modified: 15 Jul 2020 17:56 Repository Staff Only: © Copyright ,

2017 Austrian Institute of Health Technology Assessment

25. Prostate artery embolisation for benign prostatic hyperplasia

Prostate artery embolisation for benign prostatic hyperplasia Prostate artery embolisation for benign prostatic hyperplasia Prostate artery embolisation for benign prostatic hyperplasia Vreugdenburg T, Wild C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Vreugdenburg T, Wild C. Prostate artery embolisation for benign prostatic (...) commonly reported side effects associated with PAE in all studies were minor. Currently, five RCTs are ongoing comparing PAE to TURP, the end of which is scheduled for February 2021. A new evaluation is proposed in the year 2021, if results from RCTs are available by then. Project page URL Final publication URL Additional data URL Indexing Status Subject indexing assigned by CRD MeSH Arteries; Embolization, Therapeutic; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia Language Published

2017 Health Technology Assessment (HTA) Database.

26. Randomised Clinical Trial of Prostatic Artery Embolisation Versus a Sham Procedure for Benign Prostatic Hyperplasia Full Text available with Trip Pro

Randomised Clinical Trial of Prostatic Artery Embolisation Versus a Sham Procedure for Benign Prostatic Hyperplasia Prostatic artery embolisation (PAE) has been associated with an improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH), but conclusive evidence of efficacy from randomised controlled clinical trials has been lacking.To assess the safety and efficacy of PAE compared with a sham procedure in the treatment of LUTS/BPH.A randomised, single (...) associated with benign prostatic hyperplasia.Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

2020 EvidenceUpdates

27. Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for benign prostatic hyperplasia

Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for benign prostatic hyperplasia '); } else { document.write(' '); } ACE | Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for benign prostatic hyperplasia Search > > Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for benign prostatic hyperplasia - Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for the treatment of benign prostatic hyperplasia (...) Published on 2 July 2018 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Alfuzosin 10mg tablet for the treatment of benign prostatic hyperplasia. Subsidy status Alfuzosin 10mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL). SDL subsidy does not apply to tamsulosin 0.4mg tablet, dutasteride 0.5mg capsule or dutasteride 0.5mg/tamsulosin 0.4mg capsule. Factors considered to inform the recommendations for subsidy Technology evaluation Point

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

28. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia

Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia 1 Purpose Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The prevalence and the severity of lower urinary tract symptoms (LUTS) in the aging male can be progressive and is an important diagnosis in the healthcare of patients and the welfare of society. In the management (...) . magnetic resonance imaging [MRI]/ computed tomography [CT]) prior to surgical intervention for LUTS attributed to BPH. (Clinical Principle) Approved by the AUA Board of Directors May 2018 Authors’ disclosure of po- tential conflicts of interest and author/staff contribu- tions appear at the end of the article. © 2018 by the American Urological Association American Urological Association (AUA) Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE

2018 American Urological Association

29. Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (IPG475)

Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (IPG475) Overview | Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia | Guidance | NICE Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia Interventional procedures guidance [IPG475] Published date: January 2014 Share Save (...) Guidance The National Institute for Health and Care Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia, in January 2014. Description Benign prostatic hyperplasia (BPH) is a common condition that affects older men. It is characterised by an increase in the size of the prostate, which is caused by an increased number

2014 National Institute for Health and Clinical Excellence - Interventional Procedures

30. UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia

UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. UroLift System (NeoTract Inc.) for treatment of benign (...) prostatic hyperplasia. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016 Authors' objectives Current surgical treatment of benign prostatic hyperplasia (BPH) involves a transurethral resection of the prostate (TURP) requiring general or spinal anesthesia and inpatient hospitalization. TURP is associated with measureable complications, including sexual dysfunction, ejaculatory dysfunction, erectile dysfunction, urinary incontinence, bladder neck contractures, urethral stricture

2017 Health Technology Assessment (HTA) Database.

31. [Diode laser vaporization in benign prostatic hyperplasia]

[Diode laser vaporization in benign prostatic hyperplasia] [Diode laser vaporization in benign prostatic hyperplasia] [Diode laser vaporization in benign prostatic hyperplasia] Virgilio S, Alcaraz A, Pichon-Riviere A, Augustovski F,García Martí S, Bardach A, Ciapponi A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Virgilio S, Alcaraz (...) A, Pichon-Riviere A, Augustovski F,García Martí S, Bardach A, Ciapponi A. [Diode laser vaporization in benign prostatic hyperplasia] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 531. 2017 Authors' conclusions Evidence of moderate quality showed that in patients with a prostate volume of less than or equal to 80 mL, diode laser vaporization when compared with other surgical techniques

2017 Health Technology Assessment (HTA) Database.

32. Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia

Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Urolift system (NeoTract Inc.) for treatment of benign (...) prostatic hyperplasia. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Health Problem: Benign prostatic hyperplasia (BPH) is an enlargement or growth of the prostate that affects approximately 8 million men in the United States, including 30% of men older than 50 years of age and nearly 70% of men older than 70 years of age. The enlarged prostate restricts the urethra and applies pressure on the base of the bladder. This restriction of the urethra can result

2017 Health Technology Assessment (HTA) Database.

33. Prostate artery embolisation for benign prostatic hyperplasia (IPG453)

Prostate artery embolisation for benign prostatic hyperplasia (IPG453) Prostate artery embolisation for benign prostatic hyperplasia | Guidance | NICE Prostate artery embolisation for benign prostatic hyperplasia Interventional procedures guidance [IPG453] Published date: April 2013 Guidance This guidance has been updated and replaced by . Explore © NICE [year]. All rights reserved. Subject to .

2013 National Institute for Health and Clinical Excellence - Interventional Procedures

34. Chronic inflammation promotes proliferation in the prostatic stroma in rats with experimental autoimmune prostatitis: study for a novel method of inducing benign prostatic hyperplasia in a rat model. Full Text available with Trip Pro

Chronic inflammation promotes proliferation in the prostatic stroma in rats with experimental autoimmune prostatitis: study for a novel method of inducing benign prostatic hyperplasia in a rat model. Inflammation plays an important role in the development of benign prostatic hyperplasia (BPH). The aim of the present study was to reference the study of the pathological changes in the prostate gland of rats with experimental autoimmune prostatitis (EAP), for the development of experimental models (...) of BPH.Experimental autoimmune prostatitis was induced in rats by the intradermal injection of rat prostate antigen with immunoadjuvants. In case of the positive BPH group, BPH was induced by the subcutaneous injection of testosterone propionate. At the end of the 45-day model period, prostate weights were measured, and the histopathological analysis of the prostate glands was performed. The levels of cytokines, TGF-β1/RhoA/ROCK signals, and the oxidative stress status were also examined.Rats from the EAP group

2020 World journal of urology

35. Prostatic Artery Embolization in Nonindex Benign Prostatic Hyperplasia Patients: Single-center Outcomes for Urinary Retention and Gross Prostatic Hematuria. (Abstract)

Prostatic Artery Embolization in Nonindex Benign Prostatic Hyperplasia Patients: Single-center Outcomes for Urinary Retention and Gross Prostatic Hematuria. To present outcomes for prostatic artery embolization (PAE) to treat urinary retention and gross prostatic hematuria in nonindex benign prostatic hyperplasia patients.Seventy-five patients undergoing PAE from December 2013 to August 2018 (age = 77.5 ± 8.6, age-adjusted Charlson comorbidity index = 4.6 ± 2.0, prostate volume = 224 mL ± 135 (...) thereafter. Subsequently, 13/16(81%) remained hematuria-free at 500 ± 501 days; 2/16(13%) required fulguration; 1/16(6%) developed bladder tumor. There were 2 deaths <30 days post-PAE, and 8(11%) Grade-II urinary infections.PAE provided safe, effective, and durable treatment for retention and gross hematuria in nonindex benign prostatic hyperplasia patients.Copyright © 2019 Elsevier Inc. All rights reserved.

2020 Urology

36. Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression. Full Text available with Trip Pro

Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression. Prostate cancer (PC), a common malignant tumor, is the second-leading cause of cancer death among American men. Its successful treatment greatly relies on the early diagnose. Engrailed-2 (EN2) has been confirmed being existed with a high level in the urine of PC patients. In this study, to explore the application of EN2 in PC, we detected (...) the immunohistochemical staining difference and EN2 expression level between benign prostatic hyperplasia (BPH) and PC.We developed a monoclonal antibody against the helix 3 in EN2 and confirmed its specificity with Western blotting (WB) and immunofluorescence detecting the subcellular localization of endogenous and exogenous EN2 in three PC cell lines (LNCap, PC3, and DU145). We conducted immunohistochemical staining using this homemade antibody, and RT-PCR to detect the expression of EN2 in 25 PC and 25 BPH cases

2020 BMC Cancer

37. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. Full Text available with Trip Pro

Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. To compare prostatic artery embolisation (PAE) with transurethral resection of the prostate (TURP) in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia in terms of patient reported and functional outcomes.Randomised, open label, non-inferiority trial.Urology and radiology (...) departments of a Swiss tertiary care centre.103 patients aged ≥40 years with refractory lower urinary tract symptoms secondary to benign prostatic hyperplasia were randomised between 11 February 2014 and 24 May 2017; 48 and 51 patients reached the primary endpoint 12 weeks after PAE and TURP, respectively.PAE performed with 250-400 μm microspheres under local anaesthesia versus monopolar TURP performed under spinal or general anaesthesia.Primary outcome was change in international prostate symptoms score

2018 BMJ Controlled trial quality: predicted high

38. Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: 10 Years' Experience. (Abstract)

Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: 10 Years' Experience. Background Long-term experience with prostatic artery embolization (PAE) for benign prostatic hyperplasia remains limited. Purpose To evaluate the efficacy, safety, and long-term results of PAE for benign prostatic hyperplasia. Materials and Methods This retrospective single-center study was conducted from June 2008 to June 2018 in patients with moderate (...) to severe benign prostatic hyperplasia-related symptoms. International Prostate Symptom Score (IPSS), quality-of-life score, maximum urinary flow rate, postvoid residual volume, prostate-specific antigen (PSA), and prostate volume were assessed. PAE was performed with 100-500-μm embolic microspheres. Mixed-model analysis of variance and Kaplan-Meyer method was accessed, as appropriate. Results A total of 317 consecutive men (mean age ± standard deviation, 65 years ± 8) were treated. Follow-up ranged

2020 Radiology

39. Holmium laser enucleation of the prostate for very large benign prostatic hyperplasia (≥ 200 cc). (Abstract)

Holmium laser enucleation of the prostate for very large benign prostatic hyperplasia (≥ 200 cc). Patients presenting with prostate gland sizes greater than 200 cc pose a unique surgical challenge to both patients and surgeons. The objective of this study is to critically assess the efficacy and risks associated with performing holmium laser enucleation of the prostate (HoLEP) on glands ≥ 200 cc.Using a prospective maintained database, all consecutive benign prostatic hyperplasia (BPH) patients (...) not different between the two subgroups (200-299 cc vs ≥ 300 cc). Enucleation efficiency was greater for glands ≥ 300 cc (2.6 cc/min vs 2.0 cc/min, p = 0.04). Morcellation time was longer in the ≥ 300 cc group (74.5 min vs 46.8 min, p = 0.021). Mean length of stay was 1.8 ± 1.2 days and catheter duration was 2.6 ± 2.7 days. 1 (1.1%) patient required retreatment of BPH at last follow-up. The main limitation of this study is the retrospective data analysis.Holmium laser enucleation for prostate glands volume

2020 World journal of urology

40. Outcome of simultaneous thulium laser enucleation of bladder tumor and prostate in patients with non-muscle invasive bladder tumor and benign prostatic hyperplasia: a matched-pair comparison with a long-term follow-up. (Abstract)

Outcome of simultaneous thulium laser enucleation of bladder tumor and prostate in patients with non-muscle invasive bladder tumor and benign prostatic hyperplasia: a matched-pair comparison with a long-term follow-up. To access the surgical and oncological outcomes of simultaneous thulium laser enucleation of bladder tumor (ThuLEBT) and thulium laser enucleation of prostate (ThuLEP) in patients with non-muscle invasive bladder tumor (NMIBC) and benign prostatic hyperplasia (BPH).Between June (...) in catheterization period, hospital stay and complication between the two groups. At a mean follow-up of 58.7 and 55.8 months in ThuLEBT/ThuLEP group and ThuLEBT group, no significant differences in overall recurrence rates, progression rates, recurrence in the bladder neck/prostatic fossa and mean elapsed time to recurrence were detected. The 5-year recurrence-free probability was 73.2% for ThuLEBT/ThuLEP and 69.2% for ThuLEBT (p = 0.361).Our results indicate that simultaneous ThuLEBT and ThuLEP can be safely

2020 World journal of urology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>